The industry and the wider pharmaceutical sector might appreciate that the government ultimately views all these competing agendas as part of one interconnected process. It is just managing the process to maximise its control and ability to secure its desired outcomes.
The government will probably move to combine all these PBS processes into one
November 13, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Argent BioPharma advances epilepsy strategy with CannPal acquisition
April 13, 2026 - -
Telix signs new cancer development deal with Regeneron
April 13, 2026 - - Australian Biotech -
Australia risks falling further behind on access to new medicines without action, industry warns
April 13, 2026 - - Latest News -
HTA Review timeline set to extend well into the second half of 2027
April 13, 2026 - - Latest News -
The endpoint now coming into view was, in truth, always the most likely one
April 12, 2026 - - Latest News -
Cartherics and Catalent deepen partnership to accelerate next generation cell therapies
April 10, 2026 - - Australian Biotech -
Lower official co-payment but patients paying for more unsubsidised medicines
April 10, 2026 - - Latest News
